M6P Therapeutics is a privately held, venture-backed life sciences company developing first-in-class, next-generation, targeted recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs) by unlocking the potential of mannose 6-phosphate (M6P). Our first-in-class bicistronic-S1S3 technology platform enhances M6P content on lysosomal enzymes for both recombinant enzyme and gene therapies, which improves enzyme uptake across target tissues, allowing us to restore the enzymatic activity within this natural pathway.